Immunovant Awarded U.S. Patent for IMVT-1402 [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,926,669 (“the ‘669 patent”) for IMVT-1402, the Company's second-generation antibody targeting the neonatal fragment crystallizable receptor (FcRn). The allowed claims cover composition of matter for the binding sequence of IMVT-1402 to FcRn, method of use of the antibody for treating autoimmune disease, as well as methods for its manufacturing. Not including any potential patent term extension, the ‘669 patent will expire on June 23, 2043. IMVT-1402 is being developed by Immunovant based on antibody discovery efforts by HanAll Biopharma. IMVT-1402 delivered subcutaneously has demonstrated potentially best-in-class profile in a Phase 1 clinical trial in healthy adults, with initial data demonstrating a d
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Should You Hold Immunovant (IMVT)? [Yahoo! Finance]Yahoo! Finance
- Here's Why You Should Add Immunovant (IMVT) to Your Portfolio [Yahoo! Finance]Yahoo! Finance
- What Makes Immunovant (IMVT) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $50.00 price target on the stock.MarketBeat
IMVT
Earnings
- 2/12/24 - Beat
IMVT
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- IMVT's page on the SEC website